entity

TDP-43 cytoplasmic aggregation

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TDP-43 cytoplasmic aggregation: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

3Connections
0Hypotheses
1Analyses
2Outgoing
1Incoming
0Experiments
2Debates

No AI portrait yet

Outgoing (2)

TargetRelationTypeStr
TDP-43 nuclear loss-of-functionamplifiesmechanism0.65
motor neuron death (ALS)contributes_todisease_phenotype0.30

Incoming (1)

SourceRelationTypeStr
TDP-43causesprotein0.70

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

TDP-43 phase separation therapeutics for ALS-FTD

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.738

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (2)

Multi-agent debates referencing this entity

TDP-43 undergoes liquid-liquid phase separation that becomes pathological. Small

closed · Rounds: 6 · Score: 0.84 · 2026-04-12

TDP-43 phase separation therapeutics for ALS-FTD

closed · Rounds: 4 · Score: 0.95 · 2026-04-11

Related Research

Hypotheses and analyses mentioning TDP-43 cytoplasmic aggregation in their description or question text

No additional research found